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Abstract
Aims Diabetic kidney disease independently predicts cardiovascular disease and premature death. We examined the
burden of chronic kidney disease (CKD, defined as an estimated GFR < 60 ml/min/1.73 m2) and quality of care in a
cross-sectional survey of adults (age ≥ 18 years) with Type 2 diabetes across Asia.
Methods The Joint Asia Diabetes Evaluation programme is a disease-management programme implemented using an
electronic portal that systematically captures clinical characteristics of all patients enrolled. Between July 2007 and
December 2012, data on 28 110 consecutively enrolled patients (China: 3415, Hong Kong: 15 196, India: 3714, Korea:
1651, Philippines: 3364, Vietnam: 692, Taiwan: 78) were analysed.
Results In this survey, 15.9% of patients had CKD, 25.0% had microalbuminuria and 12.5% had macroalbuminuria.
Patients with CKD were less likely to achieve HbA1c < 53 mmol/mol (7.0%) (36.0% vs. 42.3%) and blood pressure
< 130/80 mmHg (20.8% vs. 35.3%), and were more likely to have retinopathy (26.2% vs. 8.7%), sensory neuropathy
(29.0% vs. 7.7%), cardiovascular disease (26.6% vs. 8.7%) and self-reported hypoglycaemia (18.9% vs. 8.2%). Despite
high frequencies of albuminuria (74.8%) and dyslipidaemia (93.0%) among CKD patients, only 49.0% were using
renin–angiotensin system inhibitors and 53.6% were on statins. On logistic regression, old age, male gender, tobacco
use, long disease duration, high HbA1c, blood pressure and BMI, and low LDL cholesterol were independently
associated with CKD (all P < 0.05).
Conclusions The poor control of risk factors, suboptimal use of organ-protective drugs and high frequencies of
hypoglycaemia highlight major treatment gaps in patients with diabetic kidney disease in Asia.
Diabet. Med. 00, 000–000 (2015)
Introduction
Diabetes mellitus is now a global pandemic as a result of
population growth, ageing and increasing rates of obesity,
with over 60% of affected individuals coming from Asia,
mainly China and India [1]. The development of diabetes
complications substantially increases healthcare expenditure,
which is fivefold higher in those with advanced chronic
kidney disease (CKD) compared with those without compli-
cations [2]. In many parts of the world, diabetes is now the
leading cause of end-stage renal disease (ESRD) and renal
replacement therapy. Reduced GFR and albuminuria have
been shown to independently predict cardiovascular disease,
congestive heart failure and all-cause mortality [3,4]. With
the onset of CKD, there is a downstream deterioration in the
metabolic milieu including anaemia, calcium–phosphateCorrespondence to: Andrea On Yan Luk. E-mail: andrealuk@cuhk.edu.hk
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homeostasis disturbances and heightened inflammation,
which collectively increase the risk of atherosclerosis [5].
Treatment to multiple targets has been shown to signifi-
cantly lower diabetes-related complications including CKD
and mortality [6,7]. International guidelines have provided
evidence-based recommendations on metabolic targets and
criteria for the use of life-saving drugs such as renin–
angiotensin system inhibitors and statins for the prevention
and treatment of diabetes complications [8]. Despite major
advances in the understanding of disease progression and
treatment effect as well as an expanding armamentarium of
therapeutics in diabetes and cardiovascular medicine, many
patients with diabetes are not managed optimally, in part due
to clinical inertia and suboptimal adherence to self-care and
medication [9–12].
The Joint Asia Diabetes Evaluation (JADE) programme is
a web-based disease-management programme that incorpo-
rates templates for metabolic and diabetes complication
screening, validated risk equations to estimate 5-year prob-
ability of major clinical events and built-in protocols to
provide decision support to physicians and patients [13,14].
Since 2007, nine countries/areas across Asia have enrolled
patients into the JADE programme as a quality improvement
initiative and for the establishment of the Asia Diabetes
Database. The primary objective of this article was to
examine the clinical profile and quality of care of patients
with Type 2 diabetes and CKD in Asia.
Patients and methods
Patients
The JADE programme is an electronic disease-management
programme with templates to guide the comprehensive
assessment of patients’ metabolic profiles and complication
status. Using built-in protocols, personalized reports are
generated to inform patients and physicians on the risk
profile of the patient, identify treatment gaps and provide
decision support. There were no entry criteria for enrolment
and patients were enrolled from diverse clinic settings
including hospital-based and community clinics, and from
the private and public sector. Between 1 July 2007 and 31
December 2012, the analysis included 28 110 consecutively
enrolled patients aged 18 years or above with Type 2
diabetes from seven regions/areas in Asia, namely China,
Hong Kong, India, Korea, Philippines, Taiwan and Vietnam,
with available serum creatinine measurements. Use of the
JADE portal for research and publication was approved by
the Joint Chinese University of Hong Kong –New Territories
East Cluster Clinical Research Ethics Committee and the
relevant institutional boards of participating sites. All
patients provided informed consent for the research team
to retrieve and analyse their anonymized data.
Complication assessment
All patients were recommended to undergo detailed
clinical assessments including documentation of their
sociodemographic profile, metabolic risk factors, history
of cardiovascular diseases and cancer, lifestyle and med-
ication. Blood pressure and anthropometric measurements
were collected. The presence of retinopathy was examined
using fundoscopy or retinal photography depending on
availability at the participating health centre. Peripheral
sensory neuropathy was determined using a graduated
tuning fork and monofilament. Sensory neuropathy was
defined by two of three criteria of self-reported abnormal
sensation in the lower extremities, reduced sensation to
monofilament, or reduced vibration sense to tuning fork
stimulation. Cardiovascular disease was defined as a
history of coronary heart disease, stroke or peripheral
vascular disease, the latter defined as non-traumatic lower
extremity amputation, a revascularization procedure for
peripheral vascular disease or an ankle–brachial index
≤ 0.9. The ankle–brachial index threshold of 0.9 is
conventionally used to define peripheral vascular disease
and increased cardiovascular risks [15]. Lifestyle aspects
included current and previous use of tobacco/alcohol, self-
monitoring of blood glucose, regular physical exercise and
adherence to a healthy diet within the previous 3 months.
Adherence to regular physical exercise was indicated by
self-report of physical activity at least three times per
week, and adherence to a healthy diet was by simple
response to yes/no question on this parameter. Hypogly-
caemia was assessed by self-report of typical hypogly-
caemia symptoms in the previous 3 months. Severe
hypoglycaemia was defined as hypoglycaemia that
required medical or non-medical third person assistance.
Blood and spot urine samples were collected for plasma
glucose, HbA1c, total cholesterol, LDL cholesterol, HDL
cholesterol, triglyceride, renal function test and urine albu-
min-to-creatinine ratio, after at least 8 h of fasting.
What’s new?
• In this large multi-national Asia diabetes database,
15% of patients had diabetic kidney disease, over a
quarter of whom had other concomitant micro- or
macrovascular complications.
• Despite their inherent high vascular risk, only one third
of patients with diabetic kidney disease achieved pre-
specified glycaemic and/or blood pressure targets and
their use of organ-protective drugs such as renin–
angiotensin system inhibitors and statins was subopti-
mal.
• This article highlights a major treatment gap in Asian
patients with diabetic kidney disease calling for greater
quality improvement effort.
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Hypertension was defined as systolic blood pressure
≥ 130 mmHg, diastolic blood pressure ≥ 80 mmHg or con-
current use of anti-hypertensive drugs. Dyslipidaemia was
defined as either LDL cholesterol ≥ 2.6 mmol/l, HDL choles-
terol < 1.0 mmol/l, triglyceride ≥ 1.7 mmol/l or concurrent
use of lipid-regulating drugs. Obesity was defined by BMI
≥ 30 kg/m2 based on World Health Organization interna-
tional definition [16]. Estimated GFR, expressed in ml/min/
1.73 m2,was calculated using the abbreviatedModification of
Diet in Renal Disease (MDRD) equation. CKDwas defined as
eGFR < 60 ml/min/1.73 m2, while ESRD was defined as
eGFR < 15 ml/min/1.73 m2 or a need for renal transplant or
dialysis.Microalbuminuria was defined as a urine albumin-to-
creatinine ratio ≥ 2.5–25.0 mg/mmol in men and ≥ 3.5–
25 mg/mmol in women, and macroalbuminuria was defined
as a urine albumin-to-creatinine ratio ≥ 25 mg/mmol.
Statistical analysis
All analysis was performed using the Statistical Package for
Social Science (SPSS v. 21.0, Chicago, IL, USA). For
descriptive analysis, continuous variables were expressed as
mean  sd or as median [interquartile range (IQR)], and
categorical variables were expressed as percentages. The
proportions of patients with CKD and albuminuria in all
seven regions/areas were reported separately with 95%
confidence intervals (CI). Comparison of baseline demo-
graphic, clinical and biochemical data as well as use of
organ-protective medications, self-management and hypo-
glycaemia was made between patients with and without
CKD. The chi-square test was used for between-group
comparison of categorical variables, t-test was used for
normally distributed continuous variables and Kruskal–
Wallis test was used for continuous variables with a skewed
distribution. Multivariable logistic regression was performed
to identify factors that were independently correlated with
CKD. Clinical variables entered into the model were selected
based on prior knowledge of possible relationships with
CKD, including age, gender, tobacco use, disease duration,
HbA1c, systolic blood pressure, LDL cholesterol, BMI, waist
circumference, urinary albumin-to-creatinine ratio, diabetic
retinopathy and sensory neuropathy. A value of P< 0.05
(two-tailed) was considered significant.
Results
In this cross-sectional cohort of 28 110 patients (China:
3415, Hong Kong: 15 196, India: 3714, Korea: 1651,
Philippines: 3364, Vietnam: 692, Taiwan: 78), the mean
age was 58.1 years, 54.1% were male and the mean duration
of diabetes was 8.2  7.6 years. The proportion of patients
with CKD was 15.9% (95% CI 15.4%–16.2%), 25.0% had
microalbuminuria (95% CI 24.4%–25.6%) and 12.5% had
macroalbuminuria (95% CI 12.1%–13.0%). The region-
specific figures are shown in Fig. 1. The frequencies of
patients with CKD ranged from 2.9% (95% CI 2.4%–3.5%)
in China to 39.8% (95% CI 38.3%–41.4%) in India,
whereas for albuminuria, the frequencies ranged from
29.0% (95% 27.4%–30.6% CI) in China to 62.7% (95%
CI 58.7%–66.6%) in Philippines.
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FIGURE 1 Proportion of patients with Type 2 diabetes with chronic kidney disease and albuminuria in seven regions/areas in Asia. The denominator
for the percentages is the number of patients with available estimated glomerular filtration rate or available urine albumin-to-creatinine ratio
measurements. Data in parentheses are the number of patients with CKD/number of patients with albuminuria.
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Table 1 Clinical characteristics of patients with Type 2 diabetes with and without chronic kidney disease (CKD) enrolled from seven regions into
the Joint Asia Diabetes Evaluation Program between 2007 and 2012
CKD (n = 4482) Non-CKD (n = 23 628) P
Demographics
Age (years) 64.4  10.6 57.0  11.2 < 0.001
Male (%) 49.3 55.1 < 0.001
Education (%)
Primary 33.2 28.1 < 0.001
Middle school 19.7 31.8
Higher school 14.8 13.3
College 32.3 26.8
Smoking (%)
Ex 18.0 28.1 < 0.001
Current 15.0 8.2
Metabolic profile
Disease duration (years) 11.6  8.5 7.6  7.2 < 0.001
BMI (kg/m2) 25.8  4.2 25.7  5.6 0.295
Waist (cm)
Male 89.0  11.0 90.8  10.4 < 0.001
Female 85.5  14.0 86.0  10.9 0.193
Systolic blood pressure (mmHg) 137.8  20.4 131.1  17.7 < 0.00‘
Diastolic blood pressure (mmHg) 78.7  10.7 78.3  10.3 0.013
HbA1c [mmol/mol (%)] 62  14 (7.8  1.8) 61  14 (7.7  1.8) < 0.001
Fasting plasma glucose (mmol/l) 8.1  3.2 8.1  2.8 0.898
Total cholesterol (mmol/l) 4.6  1.3 4.7  1.1 < 0.001
LDL cholesterol (mmol/l) 2.8  1.0 2.7  0.9 0.329
Triglyceride (mmol/l) 1.6 1.1 1.3  1.1 < 0.001
HDL cholesterol (mmol/l)
Male 1.1  0.3 1.2  0.3 < 0.001
Female 1.2  0.4 1.4  0.4 < 0.001
Estimated GFR (ml/min/1.73 m2) 46.7 (18.2) 106.5 (36.5) < 0.001
Urine albumin-to-creatinine ratio (mg/mmol) 26.8 (128.6) 1.8 (5.3) < 0.001
Hypertension (%) 95.4 80.7 < 0.001
Dyslipidaemia (%) 93.0 87.0 < 0.001
General obesity (%) 12.7 12.6 0.815
Central obesity (%) 55.0 61.3 < 0.001
Diabetes complications
Microalbuminuria (%) 27.6 24.7 0.004
Macroalbuminuria (%) 47.2 8.8 < 0.001
Retinopathy (%) 26.2 20.1 < 0.001
Sensory neuropathy (%) 29.0 7.7 < 0.001
Coronary heart disease (%) 26.6 8.7 < 0.001
Stroke (%) 7.2 4.5 < 0.001
Peripheral vascular disease (%) 9.1 6.4 < 0.001
Treatments
Lifestyle modification only (%) 27.4 21.5 < 0.001
Metformin (%) 40.3 64.2 < 0.001
Sulfonylurea (%) 35.1 35.0 0.859
Thiazolidinediones (%) 6.7 7.3 0.161
DPP-4 inhibitors (%) 9.8 4.8 < 0.001
Glucagon-like peptide-1 agonist (%) 4.3 5.4 0.001
Insulin (%) 30.9 13.3 < 0.001
Anti-hypertensive drug (%) 58.8 37.6 < 0.001
Renin–angiotensin system blockers (%) 49.0 28.8 < 0.001
Statins (%) 53.6 37.0 < 0.001
Self-reported lifestyle modification
Diet compliance (%) 45.9 52.2 < 0.001
Physical activity ≥ 3 times per week (%) 43.6 48.3 < 0.001
Self-monitoring of blood glucose (%) 53.6 59.4 < 0.001
Hypoglycaemic events ≥ once per month (%) 18.9 8.2 < 0.001
Severe hypoglycaemia in the previous 3 months 2.3 0.9 < 0.001
Attainment of treatment targets
HbA1c < 53 mmol/mol (7.0%) (%) 36.0 42.3 < 0.001
Blood pressure < 130/80 mmHg (%) 20.8 35.3 < 0.001
LDL cholesterol < 2.6 mmol/l (%) 49.2 46.2 < 0.001
One target attained 76.5 79.4 < 0.001
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The mean eGFR was 46.7 ml/min/1.73 m2 in patients with
CKD and 106.5 ml/min/1.73 m2 in those without. Among
the group with CKD, 81.7% (95% CI 80.6%–82.8%) had
an eGFR between 30 and 60 ml/min/1.73 m2, 14.9% (95%
CI 13.9%– 16.0%) had an eGFR between 15 and 30 ml/min/
1.73 m2, and 3.3% (95% CI 2.8%–3.9%) had an eGFR of
< 15 ml/min/1.73 m2. Patients with CKD were older, had a
longer disease duration, higher HbA1c, systolic blood pres-
sure and triglyceride levels, but similar LDL cholesterol levels
and BMI. They were also more likely to have macroalbu-
minuria, microalbuminuria, retinopathy, sensory neuropathy
and a history of coronary heart disease and stroke compared
with those without CKD (Table 1).
Patients with CKD were less likely to be treated with
metformin, but were more likely to be given dipeptidyl
peptidase-4 (DPP-4) inhibitor and insulin. Although more
patients with CKD were prescribed anti-hypertensive drugs,
renin–angiotensin system inhibitors and statins, the propor-
tion of patients using these agents fell short of the proportion
of patients with hypertension, albuminuria and dyslipi-
daemia. Only 62.0% (95% CI 60.9%–63.5%) of patients
identified as having hypertension were on anti-hypertensive
drugs and only 64.3% (95% CI 62.8%–65.8%) of those
with dyslipidaemia were taking statins (Fig. 2f–g). Similarly,
although 74.8% (95% CI 73.0%–76.7%) of patients with
CKD had albuminuria, renin–angiotensin system inhibitors
were prescribed in just 50.8% (95% CI 48.3%–53.3%) of
these patients (Fig. 2e) and in 49.0% of all patients with
CKD. Under-treatment despite clinical indication was
observed in all regions (Fig. 2e–g).
The proportions of patients attaining targets of HbA1c
< 53 mmol/mol (7.0%) and blood pressure < 130/80 mmHg
were lower, whereas the proportion of patients of reaching
LDL cholesterol < 2.6 mmol/l was higher in the CKD group
compared with the non-CKD group. Separated by regions, a
similar trend was observed in most, although not all, reaching
statistical significance (Fig. 2a–d). In the CKD group, 36% of
patients reached the HbA1c target, 20.8% reached the blood
pressure target, 49.6% reached the LDL cholesterol target and
3.6% reached all three targets. The respective figures for the
non-CKDgroupwere 42.3%,35.3%,46.2%and8.3%.Apart
from having worse glycaemic control, 18.9% of patients with
CKD self-reported hypoglycaemic events at least once amonth
over the previous 3 months and 2.3% had severe hypogly-
caemia. The respective figures in those without CKD were
8.2%and 0.9%.Comparedwith patients without CKD, those
with CKDweremore likely to be active smokers and less likely
to adhere to a balanced diet, perform regular exercise or self-
monitor blood glucose.
Using multiple logistic regression, old age, long disease
duration, previous tobacco use, high HbA1c, systolic blood
pressure, BMI and urinary albumin-to-creatinine ratio, but
low LDL cholesterol, diabetic retinopathy and sensory neu-
ropathy, were significantly associated with CKD (Table 2).
Variables entered but not selected by the model included
gender, current tobacco use and waist circumference.
Discussion
In this large and comprehensive dataset of patients with
Type 2 diabetes across Asia, one in six patients had CKD and
up to 40% had albuminuria. Patients with CKD had worse
metabolic control and were more likely to have other
vascular complications including coronary heart disease
and stroke. Despite being at high risk for cardiovascular
disease and mortality, fewer patients with CKD attained
glycaemic and blood pressure targets. There was also under-
usage of life-saving drugs and suboptimal self-care, with one
in five reporting recent episodes of hypoglycaemia.
Inter-ethnic differences in prevalence of diabetic kidney
disease
Several epidemiological studies have examined the preva-
lence of diabetic kidney disease in populations of mixed
ethnicities [17–19]. An international multi-ethnic study
Table 1 (Continued)
CKD (n = 4482) Non-CKD (n = 23 628) P
Two targets attained 28.2 37.3 < 0.001
Three targets attained 3.6 8.3 < 0.001
Central obesity: waist circumference ≥ 90 cm in men or ≥ 80 cm in women. General obesity: BMI ≥ 30 kg/m2. Dyslipidaemia: LDL
cholesterol ≥ 2.6 mmol/l, triglyceride ≥ 1.7 mmol/l, HDL < 1.0 mmol/l or use of lipid-lowering drugs. Hypertension: known history of
hypertension, systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 80 mmHg or use of anti-hypertensive drugs. Chronic kidney
disease: eGFR < 60 ml/min/1.73 m2. Microalbuminuria: urine albumin-to-creatinine ratio 2.5–25 mg/mmol in men or 3.5–25 mg/mmol in
women. Macroalbuminuria: urine albumin-to-creatinine ratio > 25 mg/mmol. Retinopathy: presence of background or advanced
retinopathy and/or maculopathy. Sensory neuropathy: two of three of reduced monofilament sensation, reduced vibration sensation to
graduated tuning fork testing or abnormal sensation in lower limbs. Coronary heart disease: history of myocardial infarction or coronary
intervention. Peripheral vascular disease: non-traumatic leg amputation, peripheral revascularization or ankle–brachial index < 0.9. Severe
hypoglycaemia: self-report of hypoglycaemic episode requiring medical or non-medical third person assistance. One target: achieving either
one of three targets of HbA1c < 53 mmol/mol (7.0%), blood pressure < 130/80 mmHg or LDL cholesterol < 2.6 mmol/l. Two targets:
achieving two of three targets of HbA1c < 53 mmol/mol (7.0%), blood pressure < 130/80 mmHg or LDL cholesterol < 2.6 mmol/l. Three
targets: achieving all three targets of HbA1c < 53 mmol/mol (7.0%), blood pressure < 130/80 mmHg or LDL cholesterol < 2.6 mmol/l.
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enrolling over 32 000 patients from 33 countries reported
that Asians and Hispanics were more likely to have micro-
and macroalbuminuria compared with their non-Hispanic
European counterparts. In this earlier report, albuminuria
was present in 55% of Asians and 40% of Europeans, despite
younger age and shorter disease duration in the former group
[19]. In another survey sampling 5500 patients with Type 2
diabetes and concomitant hypertension in 10 Asian coun-
tries, albuminuria was recorded in 58% of patients with a
mean disease duration of 7 years [17]. In both of these
former studies, the numbers of patients with low GFR were
not reported. In the current cohort, we documented albu-
minuria in 37% of patients and CKD in 16% of patients,
although there were marked disparities across regions with
the lowest rates of CKD and albuminuria in China and the
highest rates in India and Philippines. The excess of diabetic
kidney disease in Filipinos relative to other Asian ethnic
groups in the present analysis concurs with observations
from other contemporary studies, whereas higher frequencies
in Asian Indians have been reported less consistently [18,20].
Examination of a large managed care diabetes database in
the USA showed that among the Asian subgroups, Filipinos
had higher prevalence of CKD (37.9%) than both Chinese
(27.6%) and Asian Indians (24.8%), and Asians overall had
greater odds of having proteinuric CKD than Europeans
[20]. In a mixed ethnic cross-sectional population cohort in
Singapore, Asian Indians had a comparatively higher fre-
quency of CKD (17.6%) than Chinese (11.4%) [21].
Although the inter-ethnic disparities observed may reflect
inherent biological differences with respect to predisposition
to progressive diabetic renal injury and response to therapy,
factors including treatment, risk factors control and lifestyle
are also relevant in determining the risks of developing
complications. It should be pointed out that both Philippines
and India are largely private in health service provision,
whereas most other regions have a predominant public or
subsidized healthcare system. It is therefore possible that in
these regions, individuals with advanced disease had greater
incentives to participate in the programme and this may have
contributed to the disproportionately higher rates of com-
plications in these populations.
Metabolic control in patients with diabetic kidney disease
Several large-scale studies have now confirmed that concur-
rent CKD increased the risk of major cardiovascular event
and related death by two to threefold in patients with
diabetes [22]. The STENO study showed that intensive
global risk factor control through medication and behaviour
modification effectively prevented cardiovascular disease and
premature death in high-risk individuals with albuminuria
[6]. Despite the preventable nature of these complications, in
the USA, only 18% of patients with Type 2 diabetes reached
triple targets of glycaemia, blood pressure and cholesterol
[10]. Complex care protocols, clinical inertia, patient non-
compliance and lack of care coordination are major imped-
iments to successful management of chronic disease [23]. In
this regard, we further noted that patients with CKD were
less likely to perform self-monitoring and had worse adher-
ence to diet and regular physical exercise than the non-CKD
group. Parallel to the under-performance in self-care activ-
ities, risk factor control was worse in patients with CKD than
those without. Significantly fewer patients with CKD
achieved all three metabolic goals (3.6% vs. 8.3%), driven
by lower frequencies of target attainment in HbA1c and
blood pressure.
Table 2 Multivariable logistic regression to show the association of
clinical factors with chronic kidney disease in patients with Type 2
diabetes
Clinical variables
Odds ratio (95%
CI) P
Age 1.08 (1.08–1.09) < 0.001
Male 0.92 (0.80–1.06) 0.236
Ex smoking 1.21 (1.04–1.40) 0.015
Current smoking 0.84 (0.67–1.05) 0.132
Disease duration 1.04 (1.04–1.05) < 0.001
HbA1c 1.06 (1.02–1.10) 0.003
Systolic blood pressure 1.01 (1.00–1.01) 0.002
LDL cholesterol 0.91 (0.85–0.98) 0.007
BMI 1.04 (1.01–1.06) 0.004
Waist circumference 1.01 (1.00–1.02) 0.127
Urine albumin-to-creatinine
ratio
1.01 (1.01–1.01) < 0.001
Diabetic retinopathy 1.29 (1.15–1.46) < 0.001
Sensory neuropathy 1.67 (1.41–1.98) < 0.001
Retinopathy: presence of background or advanced retinopathy
and/or maculopathy. Sensory neuropathy: two of three of
reduced monofilament sensation, reduced vibration sensation to
graduated tuning fork testing, or abnormal sensation in lower
limbs.
FIGURE 2 (a–d) Proportion of patients with Type 2 diabetes with and without chronic kidney disease reaching: HbA1c target < 53 mmol/mol
(7.0%) by region (a), blood pressure target < 130/80 mmHg by region (b), low density-lipoprotein (LDL)-cholesterol target < 2.6 mmol/l by region
(c), and (d) all three metabolic targets of HbA1c < 53 mmol/mol (7.0%), blood pressure < 130/80 mmHg and low density-lipoprotein cholesterol
< 2.6 mmol/l by region. (e) Proportion of patients with Type 2 diabetes and albuminuria with and without chronic kidney disease being treated with
renin-angiotensin system inhibitors. (f) Proportion of patients with Type 2 diabetes and hypertension with and without chronic kidney disease being
treated with anti-hypertensive drugs. (g) Proportion of patients with Type 2 diabetes and dyslipidaemia with and without chronic kidney disease
treated with statins. The number of patients with/without CKD with valid data included in analysis is indicated in parentheses after the country/
region name. Because of the low number of patients with valid data in Taiwan, the data from this region are not shown. *P < 0.05 for comparison
between patients with and without CKD.
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Hypoglycaemia and diabetic kidney disease
Optimization of glycaemic control is challenging and prob-
lematic in patients with CKD for a number of reasons. With
a decline in renal function, the available options of anti-
diabetic agents become limited because many agents are
excreted via the renal route raising the potential for drug
accumulation. Irrespective of the anti-diabetic regimen used,
patients with CKD are at greater risk of hypoglycaemia,
which, per se, is a major barrier to meeting glycaemic targets
[24]. In our cohort, 18% of patients with CKD reported a
hypoglycaemic event at least once a month, a frequency twice
that seen in those without CKD. The association of hypo-
glycaemia with mortality has been well reported in both
cohort studies and randomized clinical trials [25,26],
although it remains unclear as to whether hypoglycaemia is
directly causal or is a surrogate for advanced disease.
Blood pressure control in patients with CKD
In this survey, 95% of patients with CKD had hypertension
similar to that reported previously [27]. However, only 20%
of patients with CKD in our cohort achieved a blood pressure
target of < 130/80 mmHg, whereas the same target was
reached in over 40% of people in a recent analysis of the
NHANES database of 4926 adults with self-reported dia-
betes between 1988 and 2010 [10]. Meticulous control of
blood pressure has been shown to retard the progression of
CKD and reduce the incidence of cardiovascular events,
particularly stroke [28,29]. Renin–angiotensin system block-
ers have additional renal protective properties beyond blood
pressure lowering. Among high-risk patients with persistent
albuminuria and impaired renal function, renin–angiotensin
system blockers were effective in lowering urinary albumin
excretion and delaying time to ESRD [30,31]. It is further
noteworthy that Asians are as responsive to renin–an-
giotensin system blockers as Caucasians [32]. In the current
database, we found that anti-hypertensive drugs were
prescribed in only 60% and renin–angiotensin system
blockers in half of patients with existing hypertension,
drawing attention to gross under-use of these agents despite
unequivocal renal benefits.
Limitations
The strength of our study is the large sample size involving
multiple Asian countries and comprehensive data collection
under a protocol. To our knowledge, few studies have
specifically addressed metabolic control in diabetic patients
with CKD. Our study has the following limitations. First,
patients enrolled in the JADE programme may not be repre-
sentative of the diabetic population in their respective coun-
tries. Although the main consideration of the JADE
programme was quality improvement in real-world practices,
given limitations in programme resources and the large
number of regions involved, it was not possible to ensure
unbiased sampling. The selection and participation of physi-
cians and patients in the programme was subjected to
influences such as physicians’ motivation and patients’ readi-
ness to be enrolled. Heterogeneity also existed in the propor-
tion of private vs. public clinics, and specialty vs. non-specialty
practices.Despite the diversity, the persistent treatment gaps in
patients with CKD in all areas highlighted the challenges in
managing this complex condition. Second, we used fixed
targets as one of the care outcomemeasures in this analysis.We
acknowledge that individualized glycaemic target is now
advocated over a ‘one-size-fit-all’ target taking into consider-
ation age, disease duration, comorbidities and life expectancy
[7]. Indeed, there is a scarcity of data on the optimal glycaemic
target in patients with CKD. Previous studies that examined
intensive vs. conventional glycaemic control have not specif-
ically included patientswith establishedCKD.The shift froma
target-driven treatment algorithm to a risk-based strategy also
pertains to themanagement of LDL cholesterol [33]. Although
we recognize the over-simplification of quantifying care
quality by targets alone, we contend that in epidemiological
research, the use of set targets enables broad examination of
performance andcomparisonbetween regions andacross time.
Third, there is a limitationon the standardizationof laboratory
assays due to the participation ofmultiple countries. Given the
largenumber of sites, eachwith their ownaffiliated laboratory,
we were also not able to obtain specific details on assay
performance and accreditation of the individual laboratory.
Up to 25% of patients were not tested for albuminuria,
possibly due to reasons such as limitations in laboratory
support, a lackoffinancial coverageor anunwillingness topay.
Fourth, because this was a cross-sectional analysis, we were
unable to examine the prognosis of patients with diabetic
kidney disease, particularly in relation to how metabolic
control may influence progression of the disease to major
vascular and renal outcomes in this group of patients.
Conclusions
In this multinational survey, we have documented the high
proportions of Asian patients with diabetic kidney disease
who had poor risk factor control, under-usage of life-saving
drugs, suboptimal self-management and frequent hypogly-
caemia. These data aim to raise awareness regarding the
importance of periodic assessment for these silent risk factors
and complications to reduce clinical inertia and improve self-
management. The incomplete data collection in some of
these patients also highlights the pressing need to address
system factors in our attempt to reduce the burden of these
comorbidities.
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